Arcus Biosciences Q3'26 Earnings Preview: EPS Estimate at (0.89) USD
Arcus Biosciences is scheduled to report Q3'26 results after the market closes on November 04. Revenue is estimated at 7.58 million USD and EPS at (0.89) USD.
Related stories
Apple CEO Says Timing of iPhone Supply-Demand Balance Is Uncertain
Apple’s CEO said the company cannot predict when iPhone supply and demand will balance.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Argentina’s Metalfor Seeks Preventive Insolvency Proceedings
The agricultural machinery manufacturer sought preventive insolvency proceedings after months of financial crisis and layoffs.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
LUX Infusion Acquires Be Well Memory’s Specialty Infusion Business
LUX Infusion says the acquisition expands access to clinician-led specialty infusion care in Nebraska.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Embraer Shares Rise More Than 4% After Greece KC-390 Order
Embraer shares rose more than 4% after Greece placed an order for KC-390 aircraft.
M impact | EQUITY | Nov 03, 2026, 03:34 PM UTC
Minda Corporation Q2 Revenue Rises 42.6% to Rs 2,189 Crore
Consolidated operating revenue increased year on year from Rs 1,535 crore in the corresponding period last year. EV products accounted for 35% of new orders.
M impact | EQUITY | Nov 03, 2026, 03:33 PM UTC
Intuitive Machines Secures Third NASA Contract in Six Months
The company will provide its spacecraft platform and system integration for NASA’s Falcon-Radar satellite. LUNR shares were up about 7% at the time of writing.
M impact | EQUITY | Nov 03, 2026, 03:32 PM UTC